Keywords: مهار کننده بازرسی ایمنی; CSF; cerebrospinal fluid; GAD; glutamic acid decarboxylase; ICI; immune checkpoint inhibitor; irAE; immune-related adverse effect; MRI; magnetic resonance imaging; PCD; paraneoplastic cerebellar degeneration; PD-1; programmed death-1;
مقالات ISI مهار کننده بازرسی ایمنی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده بازرسی ایمنی; Immunotherapy; Tumor infiltrating lymphocytes; Antigen; Immune checkpoint inhibitor; Vaccine; Type I T-cells;
Keywords: مهار کننده بازرسی ایمنی; Combination immunotherapy; Immune checkpoint inhibitor; Adverse events; Meta-analysis;
Keywords: مهار کننده بازرسی ایمنی; Immune checkpoint inhibitor; Pazopanib; Renal cell carcinoma; Resistance; VEGF;
Keywords: مهار کننده بازرسی ایمنی; cardio-oncology; checkpoint inhibitor; ipilimumab; myocarditis; nivolumab; pembrolizumab; anti-CTLA4; anti-cytotoxic T-lymphocyte-associated protein 4; anti-PD1; anti-programmed cell death protein 1; anti-PDL1; anti-programmed death-ligand 1; AUC; area un
Keywords: مهار کننده بازرسی ایمنی; Anti-PD-1; Autoimmune diabetes; Human immunodeficiency virus; Immune checkpoint inhibitor; Immune-related adverse event;
Keywords: مهار کننده بازرسی ایمنی; oncology; cancer; oncologic emergencies; checkpoint inhibitor; toxicity; toxicities; chemotherapy; immunotherapy; pneumonitis; colitis; thyroiditis; hypophysitis; dermatitis; immune checkpoint inhibitor; immunotherapy-related adverse events; irAEs; ICPI;
Keywords: مهار کننده بازرسی ایمنی; Pancytopenia; Lung cancer; Immune checkpoint inhibitor; Nivolumab; Immune related adverse event;
Keywords: مهار کننده بازرسی ایمنی; HNSCC; head and neck squamous cell carcinoma; R/M; recurrent and/or metastatic; ICPi; immune checkpoint inhibitor; irAE; immune-related adverse event; Gy; gray; MRC; Medical Research Council; CK; creatinine kinase; U/L; units per Liter; AST; aspartate tra
Keywords: مهار کننده بازرسی ایمنی; Asbestos; Immune checkpoint inhibitor; Maintenance; Programmed death-1; Prospective study;
Keywords: مهار کننده بازرسی ایمنی; Non-Small cell lung cancer; Immune checkpoint inhibitor; Drug induced pneumonitis; Risk factor;
Keywords: مهار کننده بازرسی ایمنی; Cancer of unknown primary; Targeted therapy; Monoclonal antibodies; Immune checkpoint inhibitor;
Keywords: مهار کننده بازرسی ایمنی; Drug-induced lung toxicity; Radiation; Hydrophilic polymer; Amiodarone; Immune checkpoint inhibitor;
Keywords: مهار کننده بازرسی ایمنی; Nivolumab; NSCLC; SCLC transformation; Immune checkpoint inhibitor;
Keywords: مهار کننده بازرسی ایمنی; CTLA-4; cytotoxic T-lymphocyte-associated protein 4; ICI; immune checkpoint inhibitor; irAE; immune-related adverse event; mRSS; modified Rodnan skin score; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; RNAP3; RNA polymerase III;
Keywords: مهار کننده بازرسی ایمنی; Acute pneumonitis; Afatinib; Anti PD-1 antibody; Immune checkpoint inhibitor; EGFR-TKI; epidermal growth factor receptor-tyrosine kinase inhibitor; PD-1; programmed cell death-1; PD-L1; programmed cell death ligand-1; NSCLC; non-small cell lung cancer; BA
Keywords: مهار کننده بازرسی ایمنی; Melanoma; Metastatic; Network meta-analysis; Targeted therapy; Immune checkpoint inhibitor;
Keywords: مهار کننده بازرسی ایمنی; Prostate cancer; Metastatic; Castration-resistant; Immunotherapy; Immune checkpoint inhibitor; Vaccines; Oncolytic viruses;
Keywords: مهار کننده بازرسی ایمنی; DNA mismatch repair; DNA polymerase epsilon; Microsatellite instability; Colorectal cancer; Endometrial cancer; Neoantigen; Immune signature; Immunotherapy; Immune checkpoint inhibitor;
Keywords: مهار کننده بازرسی ایمنی; Adoptive immunotherapy; Antibody-drug conjugate; Immune checkpoint inhibitor; Recombinant Bacillus Calmette-Guérin; Therapeutic cancer vaccine;
Keywords: مهار کننده بازرسی ایمنی; Ab; antibody; BM; bone marrow; CA; carbonic anhydrase; CCL; C-C motif chemokine ligand; CTL; cytotoxic T lymphocyte; DC; dendritic cell; FAO; fatty acid oxidation; GPCR; G-protein-coupled receptors; ICI; immune checkpoint inhibitor; IL; interleukin; mAbs;
Keywords: مهار کننده بازرسی ایمنی; Programmed cell death 1; PD-1; PDCD1; anti-PD-1 antibody; PD-1 inhibitor; nivolumab; pembrolizumab; acute interstitial nephritis (AIN); acute kidney injury (AKI); non-small cell lung cancer (NSCLC); advanced melanoma; ipilimumab; immune checkpoint inhib
Keywords: مهار کننده بازرسی ایمنی; Tumor microenvironment; Adaptive immunity; Breast cancer; Colon cancer; Immune checkpoint inhibitor; Inflammation
Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barré syndrome
Keywords: مهار کننده بازرسی ایمنی; Nivolumab; Immune checkpoint inhibitor; Guillain-Barré syndrome; Polyneuropathy;
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
Keywords: مهار کننده بازرسی ایمنی; Atezolizumab; Non-small-cell lung cancer; PD-L1; Immune checkpoint inhibitor;
Postoperative anti-PD-1 antibody treatment to reduce recurrence in a cancer ablation surgical wound
Keywords: مهار کننده بازرسی ایمنی; Head and neck cancer; Surgery; Tumor recurrence; Immune checkpoint inhibitor; Antitumor immunity;
Recent Developments in Oncology Immunotherapy, Implications for NPs Part 1
Keywords: مهار کننده بازرسی ایمنی; cytotoxic T-lymphocyte antigen 4; immune checkpoint inhibitor; immune-related adverse event; immunotherapy; nurse practitioner; programmed cell death 1; programmed death-ligand 1;
Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer
Keywords: مهار کننده بازرسی ایمنی; PD-L1; Immune checkpoint inhibitor; Immune stromal PD-L1; Rectal cancer; CD8; T cell; Chemoradiotherapy; Immunotherapy; Tumour-infiltrating lymphocyte; Synergistic effect;
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Keywords: مهار کننده بازرسی ایمنی; CRS; cytokine release syndrome; CTL; cytotoxic T lymphocyte; EC50; half maximal effective concentration; Fc; fragment crystallizable; ICI; immune checkpoint inhibitor; pMHC; peptide-major histocompatibility complex; scFv; single chain variable fragment; T
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy
Keywords: مهار کننده بازرسی ایمنی; Tumor-infiltrating lymphocytes; Non-small cell lung cancer; Immune checkpoint inhibitor; Regulatory T cells; Tumor microenvironment;
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer
Keywords: مهار کننده بازرسی ایمنی; Health-related quality of life; Immune checkpoint inhibitor; Immunotherapy; Patient-reported outcomes; PD-L1;
Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
Keywords: مهار کننده بازرسی ایمنی; Anti-PD-1 antibody; Biomarker; Immune checkpoint inhibitor; Immunotherapy; Kidney cancer;
DNA mismatch repair in cancer
Keywords: مهار کننده بازرسی ایمنی; 5-FU; 5-fluorouracil; bMMRD; Biallelic mismatch repair deficiency; CD28; cluster of differentiation 28; CIN; Chromosomal instable; CR; complete response; CRC; colorectal cancer; CTL; cytotoxic T-lymphocytes; CTLA-4; cytotoxic T lymphocyte antigen-4; DFS;
Immuno-radiotherapyRadiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation
Keywords: مهار کننده بازرسی ایمنی; Immunotherapy; Immune checkpoint inhibitor; Radiation therapy;
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
Keywords: مهار کننده بازرسی ایمنی; Advanced renal cell carcinoma; Immune checkpoint inhibitor; Immunotherapy agents; Nivolumab; Second-line therapy; PD-1 inhibitor;
ReviewImmunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
Keywords: مهار کننده بازرسی ایمنی; Non-small-cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab; Nivolumab; Atezolizumab; PDL1; PD1;
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Keywords: مهار کننده بازرسی ایمنی; Everolimus; Immune checkpoint inhibitor; Nivolumab; Phase 3; Renal cell carcinoma;
Polymyositis induced by PD-1 blockade in a patient in hepatitis B remission
Keywords: مهار کننده بازرسی ایمنی; Immune-checkpoint inhibitors; Polymyositis; Immunological memory; Molecular mimicry; HBV; hepatitis B virus; ICI; immune checkpoint inhibitor; ICIM; immune checkpoint inhibitor-induced myopathy; IIM; idiopathic inflammatory myopathy; IRAE; immune-related
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: AÂ Prospective Cohort Study
Keywords: مهار کننده بازرسی ایمنی; Immune checkpoint inhibitor; Immune-related adverse event; Nivolumab; Non-small cell lung cancer; Programmed cell death ligand 1;
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Keywords: مهار کننده بازرسی ایمنی; AAH; atypical adenomatous hyperplasia; AK; actinic keratosis; AML; acute myelogenous leukemia; AMM; asymptomatic multiple myeloma; APC; antigen presenting cell; B-ALL; B cell acute lymphocytic leukemia; B-CLL; B cell chronic lymphocytic leukemia; BD; Bowe
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma
Keywords: مهار کننده بازرسی ایمنی; CTLA-4; Head and neck squamous cell carcinoma; Immune checkpoint inhibitor; Immunotherapy; PD-1; Tumor microenvironment; VISTA
Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity
Keywords: مهار کننده بازرسی ایمنی; Cryoablation; ALCAM; Mesenchymal stem cell; Immunosuppression; Immune checkpoint inhibitor;
Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis
Keywords: مهار کننده بازرسی ایمنی; nSMOL; nano-surface and molecular-orientation limited proteolysis; Nivolumab; Immune checkpoint inhibitor; Monoclonal antibody; nSMOL; Bioanalysis; LCMS;
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
Keywords: مهار کننده بازرسی ایمنی; Age; Immune checkpoint inhibitor; Immunosenescence; Meta-analysis; Overall survival; Progression-free survival; Systematic review;
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies
Keywords: مهار کننده بازرسی ایمنی; Non-small cell lung cancer; Anti-PD-1 antibody; Anti-PD-L1 antibody; Immune checkpoint inhibitor; Alternative end point; Overall survival;